Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Other, SGLT2i Aug 26 | 2022AZ to Initiate Ph2 Dapa + Zibotentan Trial in Cirrhosis; Esperion’s BA Included in ACC's ECDP GuidelinesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Other Aug 25 | 2022"Mass" Layoff at Beta Bionics?; Novo Initiates Ph3 Ozempic + Lower-Dose Glargine Trial; Novartis to Spin Off Sandoz; Lannett and Adocia CY Q2 ’22 Earnings Updates; Hygieia Appoints New CEOPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Aug 23 | 2022Medtronic CY Q2 ‘22 Earnings Updates; Glytec Collaborates with CPS for Glycemic Management TechnologyPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Aug 22 | 2022Novo Announces Positive Ph2 Cagrisema Results; Insulet’s Omnipod 5 Receives Expanded FDA Clearance; Digbi Health Enrolled in Novo’s Accelerator Program; New Lyumjev Trial for Inreda’s Bi-hormonal AID System; Amarin Discontinues Vazkepa in GermanyPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring Aug 19 | 2022Novo Withdraws PIONEER START Trial; Onduo Partners with Sword Health; Nemaura and Movano Q2 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other Aug 16 | 2022Sean Saint Takes Over as Beta Bionics CEOPurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i Aug 16 | 2022DELIVER Filed in US? August 2022 CHMP AgendaPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Aug 15 | 2022Abbott Expands CGM Manufacturing Capacity; Dario and Embecta Q2 ‘22 Earnings UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, Glucagon, Insulin Delivery, Other Aug 11 | 2022Xeris, Zealand, and MannKind Q2 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: DPP-IVi, Glucose Monitoring, Other Aug 09 | 2022FDA Detects Impurities in Samples of Merck’s Januvia; Senseonics and Ionis Q2 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Other Aug 08 | 2022Gan & Lee GZR4 IND Granted FDA Clearance; Viatris Q2 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Aug 05 | 2022Novo Q2 ’22 London Earnings; Vertex and Amgen Q2 ’22 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Aug 04 | 2022Insulet, Provention Bio, Bayer, and Regeneron Q2 ‘22 Earnings Updates; Abbott Partners with WeightWatchersPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Insulin Delivery, Other Aug 04 | 2022Mounjaro Off to an Impressive Start; Lilly Q2 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Insulin Delivery, Other Aug 04 | 2022Tandem, Amarin, and Intercept Q2 ’22 Earnings Updates; Anthem to Cover Eversense E3 Implantable CGMPurchase Blast
$599
Posted in: GLP-1RA, Other Aug 03 | 2022SELECT Doesn’t Stop at Interim Analysis; Novo Nordisk Q2 ’22 Earnings UpdatePurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, SGLT2i Aug 02 | 2022Lexicon Q2 ’22 Earnings Update; CLEAR Outcomes CVOT Reaches 100% MACE Accumulation; Esperion Q2 ’22 Earnings Update; Dexcom ONE Available with Prescription in UK; Gan & Lee Dose First Patient in Ph2 GZR18 Trial for T2DM; Structure Therapeutics Advances Diabetes & Obesity Clinical ProgramPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Aug 01 | 2022Insulet Initiates Omnipod 5 US Broad Launch; Arecor Buys Tetris Pharma; Sanofi/Optum Partner for Insulin AffordabilityPurchase Blast
$599
Posted in: Basal Insulin, Other, SGLT2i Jul 29 | 2022Novo’s QW Insulin Icodec Meets Primary Endpoints in ONWARDS 3 and 4; AZ and Alnylam Q2 ’22 earnings updates; Better Therapeutics Meets Secondary Endpoint in BT-001 Pivotal Trial in T2DMPurchase Blast